Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic pain
Biotech
Lilly lands next-gen pain asset in $1B SiteOne acquisition
SiteOne's lead sodium channel inhibitor was well-tolerated and improved patients' pain tolerances in a recent phase 1 trial.
Darren Incorvaia
May 27, 2025 11:30am
Fecal transplants alleviate fibromyalgia pain in small trial
Apr 28, 2025 7:30am
Latigo saddles up with $150M to advance non-opioid pain assets
Mar 17, 2025 5:00am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Remedee nabs EU approval for fibromyalgia wristband therapy
Sep 30, 2024 2:00pm
CRO Lotus' founder leaps to Latigo
Aug 20, 2024 1:59pm
